Auron Therapeutics
WELLESLEY, MA · Biotechnology · 200 employees
Auron Therapeutics is a platform-based, product-driven biotechnology company focused on developing therapies that target cellular plasticity for solid tumor cancers and hematological malignancies. Auron has built a proprietary AI-powered platform that integrates large, multi-omic datasets to rapidly compare tumor tissue to normal tissues and enable a systems-biology understanding of the pathways t
Funding history
- Funding Round — $27.3M — Dec 2025
- Funding Round — $13.4M — Dec 2024
- Funding Round — $38.4M — Oct 2023
- Funding Round — $26.0M — Jul 2022
- Series SERIES A — $48.0M — Jul 2022
Recent signals
- Dec 23, 2025: Raised $27.3M
- Dec 31, 2024: Raised $13.4M
- Oct 20, 2023: Raised $38.4M
- Jul 28, 2022: Raised $26.0M
- Jul 20, 2022: Raised $48.0M in Series SERIES A
- Dec 16, 2020: Raised $15.4M
- Jul 25, 2018: Raised $27.3M
See plans & pricing → Track Auron Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.